How big is GeoVax Labs, Inc.?

As of Jun 18, GeoVax Labs, Inc. has a market capitalization of 14.33 million, with net sales of 5.59 million and a net profit of -24.50 million over the latest four quarters. The company's shareholder's funds are 5.05 million, and total assets are 8.16 million.

Market Cap: As of Jun 18, GeoVax Labs, Inc. has a market capitalization of 14.33 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, GeoVax Labs, Inc. reported net sales of 5.59 million and a net profit of -24.50 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 5.05 million, while total assets were reported at 8.16 million.

What does GeoVax Labs, Inc. do?

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing human vaccines for infectious diseases. It has a market cap of $14.33 million, with recent net sales of $2 million and a net loss of $5 million.

Overview:<BR>GeoVax Labs, Inc. is a clinical-stage biotechnology company engaged in developing human vaccines against infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 14.33 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.94 <BR>Return on Equity: -310.20% <BR>Price to Book: 1.81<BR><BR>Contact Details:<BR>Address: Suite 380, SMYRNA GA: 30080 <BR>Tel: 1 678 3847220 <BR>Fax: 1 302 6555049 <BR>Website: https://www.geovax.com/

Should I buy, sell or hold GeoVax Labs, Inc.?

Who are in the management team of GeoVax Labs, Inc.?

As of March 2022, the management team of GeoVax Labs, Inc. includes Mr. David Dodd as Chairman, President, and CEO, along with Directors Dr. Robert McNally, Dr. Randal Chase, Mr. Dean Kollintzas, and Mr. John Spencer.

As of March 2022, the management team of GeoVax Labs, Inc. includes Mr. David Dodd, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Dr. Robert McNally as a Director, Dr. Randal Chase as an Independent Director, Mr. Dean Kollintzas as an Independent Director, and Mr. John Spencer as an Independent Director.

Is GeoVax Labs, Inc. overvalued or undervalued?

As of November 12, 2024, GeoVax Labs, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 2.15 and a year-to-date return of -73.22%, significantly underperforming the S&P 500.

As of 12 November 2024, the valuation grade for GeoVax Labs, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial health. The company appears to be overvalued given its troubling financial metrics, including a Price to Book Value of 2.15, an EV to Sales ratio of 1.71, and an EV to Capital Employed of 9.58, which suggest that investors are paying a premium for the company's assets despite its poor performance.<BR><BR>In comparison to its peers, GeoVax's valuation ratios are concerning; for instance, Catalyst Biosciences, Inc. is classified as expensive with a P/E ratio of 110.04, while Elutia, Inc. and 22nd Century Group, Inc. are both deemed risky with negative EV to EBITDA ratios of -5.54 and -0.62, respectively. Furthermore, GeoVax's stock has significantly underperformed against the S&P 500, with a year-to-date return of -73.22% compared to the index's 12.22%, reinforcing the notion that the company is currently overvalued.

Is GeoVax Labs, Inc. technically bullish or bearish?

As of June 13, 2025, GeoVax Labs, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and Bollinger Bands, despite a mildly bullish MACD, with a year-to-date return of -73.22% compared to the S&P 500's 12.22%.

As of 13 June 2025, the technical trend for GeoVax Labs, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by daily moving averages indicating a bearish trend and Bollinger Bands showing bearish signals on both weekly and monthly time frames. Although the MACD is mildly bullish on weekly and monthly charts, this is countered by the overall bearish indicators from moving averages and Bollinger Bands. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -73.22% versus the S&P 500's 12.22%.